| Citation: |
ZENG Lulu, JI Xiaojian, HU Lidong, HU Jiawen, ZHANG Yinan, ZHANG Jiaxin, LIU Xingkang, YANG Shiwei, HUANG Feng. Clinical Characteristics and Treatment Options of Peripheral Spondyloarthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 50-58. DOI: 10.12290/xhyxzz.2024-0394
|
To compare the differences in clinical features and treatment choices between peripheral spondyloarthritis(pSpA) and axial spondyloarthritis(axSpA), and better understand the clinical characteristics and medication needs of pSpA.
Our study is a retrospective cohort study. The patients who first visited the First Medical Center of Chinese PLA General Hospital between January 2016 and December 2022 and were diagnosed with axSpA or pSpA according to the classification criteria established by the Assessment of SpondyloArthritis International Society were selected as the study subjects. Demographic data, clinical characteristics, laboratory tests, and treatment information of these patients were obtained through the electronic medical records management system and the intelligent management system for spondyloarthritis. The research compared the distribution of swollen and tender joints between pSpA and axSpA patients, as well as that between pSpA1(excluding patients with psoriatic arthritis) and axSpA patients. Additionally, we analyzed differences in clinical features and treatment options among these groups.
A total of 1639 patients were included in the study, of which 184 had pSpA(including 97 with psoriatic arthritis), and 1455 had axSpA. Compared to axSpA patients, pSpA patients had fewer male patients(62.5% vs. 79.7%, P < 0.001), later onset age(33.8 years vs. 22.0 years, P < 0.001), shorter diagnostic delays(6.0 months vs. 14.2 months, P=0.004), more associated peripheral arthritis(71.7% vs. 9.3%, P < 0.001) and dactylitis(6.5% vs. 0.3%, P < 0.001), more cases of psoriasis(52.7% vs. 1.1%, P < 0.001) and a more common family history of psoriasis(11.4% vs. 3.4%, P < 0.001). pSpA patients had higher levels of inflammatory markers but a lower positive rate of human leukocyte antigen(HLA)-B27(43.5% vs. 87.4%, P < 0.001). A positive HLA-B27 was associated with an earlier onset age, fewer cases of psoriasis, and a family history of ankylosing spondylitis. pSpA patients had a higher proportion of using conventional synthetic disease-modifying antirheumatic drugs(csDMARDs), biologic disease-modifying antirheumatic drugs(bDMARDs), and oral glucocorticoids, and they also more frequently used a combination of bDMARDs and csDMARDs(19.0% vs. 12.2%, P=0.009) or multiple csDMARDs(65.8% vs. 12.5%, P < 0.001). Compared to axSpA patients, pSpA1 patients(excluding psoriatic arthritis) did not show significant differences in the prevalence of psoriasis, uveitis, family history of psoriasis, or the use of bDMARDs, but the subgroup analysis of other variables was consistent with the results of pSpA patients.
pSpA patients tend to have a later onset of disease, a lower proportion of male and HLA-B27 positivity, more associated peripheral arthritis, dactylitis, psoriasis, and a more common family history of psoriasis. The disease burden in terms of treatment for pSpA is not lower than that for axSpA. Due to the presence of more peripheral symptoms, psoriasis, and higher levels of inflammation, they also require more medication.
| [1] |
Rudwaleit M, Landewé R, Van Der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis(part Ⅰ): classification of paper patients by expert opinion including uncertainty appraisal[J]. Ann Rheum Dis, 2009, 68(6): 770-776. DOI: 10.1136/ard.2009.108217
|
| [2] |
Zeidler H, Amor B. The Assessment in Spondyloarthritis International Society(ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress[J]. Ann Rheum Dis, 2011, 70(1): 1-3. DOI: 10.1136/ard.2010.135889
|
| [3] |
López-Medina C, Molto A, Sieper J, et al. Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study[J]. RMD Open, 2021, 7(1): e001450. DOI: 10.1136/rmdopen-2020-001450
|
| [4] |
Carron P, De Craemer A S, Van Den Bosch F. Peripheral spondyloarthritis: a neglected entity-state of the art[J]. RMD Open, 2020, 6(1): e001136. DOI: 10.1136/rmdopen-2019-001136
|
| [5] |
Carron P, Varkas G, Cypers H, et al. Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study[J]. Ann Rheum Dis, 2017, 76(8): 1389-1395. DOI: 10.1136/annrheumdis-2016-210775
|
| [6] |
Mease P, Sieper J, Van Den Bosch F, et al. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis[J]. Arthritis Rheumatol, 2015, 67(4): 914-923. DOI: 10.1002/art.39008
|
| [7] |
López-Medina C, Dougados M, Ruyssen-Witrand A, et al. Evaluation of concomitant peripheral arthritis in patients with recent onset axial spondyloarthritis: 5-year results from the DESIR cohort[J]. Arthritis Res Ther, 2019, 21(1): 139. DOI: 10.1186/s13075-019-1927-6
|
| [8] |
Kwan Y H, Fong W, Leung Y Y, et al. Are extra-spinal symptoms associated with quality of life in patients with axial spondyloarthritis? A 1-year follow-up study[J]. Clin Rheumatol, 2019, 38(7): 1881-1887. DOI: 10.1007/s10067-019-04514-4
|
| [9] |
López-Medina C, Chevret S, Molto A, et al. Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study[J]. RMD Open, 2021, 7(3): e001728. DOI: 10.1136/rmdopen-2021-001728
|
| [10] |
Solmaz D, Bakirci S, Jibri Z, et al. Psoriasis is an independent risk factor for entheseal damage in axial spondyloarthritis[J]. Semin Arthritis Rheum, 2020, 50(1): 42-47. DOI: 10.1016/j.semarthrit.2019.06.016
|
| [11] |
Skare T L, Leite N, Bortoluzzo A B, et al. Effect of age at disease onset in the clinical profile of spondyloarthritis: a study of 1424 Brazilian patients[J]. Clin Exp Rheumatol, 2012, 30(3): 351-357.
|
| [12] |
Arevalo Salaet M, López-Medina C, Moreno M, et al. Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study[J]. RMD Open, 2022, 8(2): e002696. DOI: 10.1136/rmdopen-2022-002696
|
| [13] |
López-Medina C, Ortega-Castro R, Castro-Villegas M C, et al. Axial and peripheral spondyloarthritis: does psoriasis influence the clinical expression and disease burden? Data from REGISPONSER registry[J]. Rheumatology(Oxford), 2021, 60(3): 1125-1136. DOI: 10.1093/rheumatology/keaa398
|
| [14] |
Boel A, Van Lunteren M, López-Medina C, et al. Geographical prevalence of family history in patients with axial spondyloarthritis and its association with HLA-B27 in the ASAS-PerSpA study[J]. RMD Open, 2022, 8(1): e002174. DOI: 10.1136/rmdopen-2021-002174
|
| [15] |
Navarro-Compán V, Benavent D, Capelusnik D, et al. ASAS consensus definition of early axial spondyloarthritis[J]. Ann Rheum Dis, 2024, 83(9): 1093-1099. DOI: 10.1136/ard-2023-224232
|
| [16] |
Ogdie A, Nowell W B, Applegate E, et al. Patient perspectives on the pathway to psoriatic arthritis diagnosis: results from a web-based survey of patients in the United States[J]. BMC Rheumatol, 2020, 4: 2. DOI: 10.1186/s41927-019-0102-7
|
| [17] |
Tillett W, Charlton R, Nightingale A, et al. Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort[J]. Rheumatology(Oxford), 2017, 56(12): 2109-2113. DOI: 10.1093/rheumatology/kex323
|
| [18] |
Poddubnyy D, Jadon D R, Van Den Bosch F, et al. Axial involvement in psoriatic arthritis: an update for rheumatologists[J]. Semin Arthritis Rheum, 2021, 51(4): 880-887. DOI: 10.1016/j.semarthrit.2021.06.006
|
| [19] |
Lorenzin M, Ortolan A, Vio S, et al. Psoriasis and imaging progression in early axial spondyloarthritis: results from a 48-month follow-up(Italian arm of SPACE study)[J]. Rheumatology(Oxford), 2022, 61(6): 2375-2387. DOI: 10.1093/rheumatology/keab728
|
| [20] |
Lorenzin M, Cozzi G, Scagnellato L, et al. Relationship between sex and clinical and imaging features of early axial spondyloarthritis: results from a 48 month follow-up(Italian arm of the SPondyloArthritis Caught Early(SPACE) study)[J]. Scand J Rheumatol, 2023, 52(5): 519-529. DOI: 10.1080/03009742.2023.2169990
|
| [21] |
Zabotti A, Luchetti M M, Selmi C F, et al. An Italian disease-based registry of axial and peripheral spondyloarthritis: the SIRENA study[J]. Front Med(Lausanne), 2021, 8: 711875.
|
| [22] |
De Bruin F, Ter Horst S, Bloem H L, et al. Prevalence of degenerative changes of the spine on magnetic resonance images and radiographs in patients aged 16-45 years with chronic back pain of short duration in the Spondyloarthritis Caught Early(SPACE) cohort[J]. Rheumatology(Oxford), 2016, 55(1): 56-65. DOI: 10.1093/rheumatology/kev283
|
| [23] |
Renson T, Carron P, De Craemer A S, et al. Axial involvement in patients with early peripheral spondyloarthritis: a prospective MRI study of sacroiliac joints and spine[J]. Ann Rheum Dis, 2021, 80(1): 103-108. DOI: 10.1136/annrheumdis-2020-218480
|
| [24] |
Smolen J S, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force[J]. Ann Rheum Dis, 2018, 77(1): 3-17. DOI: 10.1136/annrheumdis-2017-211734
|
| [25] |
Derakhshan M H, Dean L, Jones G T, et al. Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis[J]. RMD Open, 2020, 6(2): e001206. DOI: 10.1136/rmdopen-2020-001206
|
| [26] |
Molto A, Sieper J. Peripheral spondyloarthritis: concept, diagnosis and treatment[J]. Best Pract Res Clin Rheumatol, 2018, 32(3): 357-368. DOI: 10.1016/j.berh.2019.02.010
|
| [27] |
Behrens F, Cañete J D, Olivieri I, et al. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature[J]. Rheumatology(Oxford), 2015, 54(5): 915-926. DOI: 10.1093/rheumatology/keu415
|
| [1] | LU Chaofan, LENG Xiaomei. Advances in the Drugs Treatment of Psoriatic Arthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 65-74. DOI: 10.12290/xhyxzz.2024-0820 |
| [2] | CUI Hanshu, LIU Bin. Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 13-18. DOI: 10.12290/xhyxzz.2024-0802 |
| [3] | YANG Xiaoxi, TIAN Xinping, LI Mengtao, LENG Xiaomei, ZHAO Yan, ZENG Xiaofeng. Interpretation on the Consensus on Targeted Drug Therapy for Spondyloarthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(1): 58-67. DOI: 10.12290/xhyxzz.2023-0391 |
| [4] | LIU Huan, HUANG Xiaoling, DAI Mengying, GUO Jiejie, GAO feng. Clinical Characteristics and Inflammatory Markers of Omicron BA.5.2 Variant Infection in Hospitalized Patients and Their Predictive Role in Disease Prognosis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1038-1045. DOI: 10.12290/xhyxzz.2023-0055 |
| [5] | CHENG Yuejuan, GUAN Mei, WANG Xiang, BAI Chunmei. Novel Treatment Strategies for Advanced Pancreatic Ductal Adenocarcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 341-348. DOI: 10.12290/xhyxzz.2021-0139 |
| [6] | ZHAO Zhe, TANG Yan, ZHOU Jingya, CHEN Xiaoguang, ZHANG Lei, CHEN Limeng, YUAN Tao. Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 277-286. DOI: 10.12290/xhyxzz.2021-0180 |
| [7] | HAN Jie, YU Hong. Progress in Immune Markers and Relevant Drug Therapies of Mycosis Fungoides[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 568-574. DOI: 10.12290/xhyxzz.20200278 |
| [8] | Mei GUAN, Chun-mei BAI. Medical Treatment for Biliary Tract Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 325-333. DOI: 10.3969/j.issn.1674-9081.20190247 |
| [9] | Jia-qi ZHANG, Lei LIU, Gui-ge WANG, Wen-liang BAI, Shan-qing LI. Clinical Pathological Features and Prognosis of Non-small Cell Lung Cancer with Skip N2 Lymph Node Metastasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 272-277. DOI: 10.3969/j.issn.1674-9081.2019.03.015 |
| [10] | Ming-sheng MA, Xü-de ZHANG, Min WEI, Shi-min ZHAO, Zheng-qing QIU. Efficacy of Low Dose Corticosteroid Therapy in Duchenne Muscular Dystrophy[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(4): 384-388. DOI: 10.3969/j.issn.1674-9081.2014.04.006 |
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: